Clinical Trials Logo

Clinical Trial Summary

A desirable quality of mouthrinses is substantivity an intrinsic feature of some molecules. Substantivity requires the adsorption of the agent on the oral surfaces and subsequently antimicrobial activity bacteriostatic along following hours. This work aims to quantitatively determine the substantivity of (i) a single o-Cymen-5-ol plus CPC oral rinse, (ii) a, CPC oral rinse and (iii) a o-Cymen-5-ol mouthwash on the salivary microbiota up to 4 h after their application.


Clinical Trial Description

One of the desirable qualities of mouthrinses is substantivity, which is defined as the persistence capacity of its antimicrobial action over time in the mouth. This is an intrinsic feature of some molecules. Such substantivity seems to require the adsorption of the agent on the buccal surfaces and subsequently exert a certain antimicrobial activity that seems to be mostly bacteriostatic. Substantivity is the result of multiple factors controlling or altering adhesion, life period of antimicrobial capabilities, synergisms, antagonisms, and others. In order to improve substantivity and therefore increase antimicrobial effectiveness of CPC, o-Cymen-5-ol has recently been proposed to become incorporated to oral rinses. The aim of this work is to quantitatively determine the substantivity of (i) a single o-Cymen-5-ol plus CPC oral rinse, (ii) a, CPC oral rinse and (iii) a o-Cymen-5-ol mouthwash on the salivary microbiota up to 4 h after their application. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05365737
Study type Interventional
Source University of Barcelona
Contact
Status Completed
Phase N/A
Start date January 1, 2022
Completion date February 3, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04062578 - Effects Provided by a Physiotherapy Treatment Preventing Lower Extremity Injuries in Female Football Players N/A
Not yet recruiting NCT04400019 - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Phase 2/Phase 3
Completed NCT00793455 - Outreach for Patients With Uncompleted Colorectal Cancer Screening Orders N/A
Completed NCT00563264 - KAN-DO: A Family-based Intervention to Prevent Childhood Obesity N/A
Completed NCT05261152 - S. Boulardii in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adults With Respiratory Tract Infections Phase 4
Completed NCT02165709 - Cohort Study of Risk Reducing Salpingectomy N/A
Recruiting NCT06164600 - Bovine Colostrum for Prophylaxis Against Recurrent Urinary Tract Infection in Children Phase 2
Completed NCT01776424 - Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease Phase 3
Enrolling by invitation NCT02580279 - Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy Phase 2
Recruiting NCT01747278 - Study of Trimethoprim/Sulfamethoxazole as PCP Prophylaxis in CTD Patients Phase 2/Phase 3
Enrolling by invitation NCT02577393 - Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy Phase 2
Withdrawn NCT01137591 - Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever N/A